市場調查報告書
商品編碼
1086983

口服給藥:市場預測(2022-2027)

Oral Drug Delivery Market - Forecasts from 2022 to 2027

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 111 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2020年全球口服給藥市場規模將達到983.02億美元,預測期內復合年增長率為6.04%,預計到2027年將達到1442.01億美元。

口服給藥被認為是最常見的給藥方法,因為它是非侵入性的,患者依從率高,易於處理,並且不需要特殊的無菌條件。因此,受到廣大消費者的青睞。在預測期內,預計將有多種因素推動市場發展,包括市場參與者之間夥伴關係的增加、慢性病發病率的增加以及全球老年人口的增加。

本報告對全球口服給藥市場進行了調查,包括市場規模和預測、市場驅動因素和挑戰、市場趨勢、按配方/用途/地區進行的市場分析、競爭形勢和主要公司。它提供了概況等系統信息。

目錄

第一章介紹

  • 市場定義
  • 市場細分

第二章調查方法

  • 調查數據
  • 先決條件

第 3 章執行摘要

  • 調查重點

第四章市場動態

  • 市場促進因素
  • 市場製約因素
  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代威脅
    • 新進入者的威脅
    • 競爭對手之間的敵對關係
  • 產業價值鏈分析

第 5 章口服給藥市場:按配方

  • 簡介
  • 片劑
  • 膠囊
  • 掉落
  • 液體/糖漿

第 6 章口服給藥市場:按用途

  • 簡介
  • 治療疾病
  • 研究/學術目的

第 7 章口服給藥市場:按地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙特阿拉伯
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 印度
    • 泰國
    • 韓國
    • 台灣
    • 印度尼西亞
    • 其他

第8章競爭環境與分析

  • 主要公司及戰略分析
  • 初創企業和市場盈利能力
  • 合併、收購、協議和合作
  • 供應商競爭力矩陣

第 9 章公司簡介

  • Pfizer Inc.
  • AstraZeneca
  • Alpex Pharma S.A.
  • SPI Pharma
  • Globela Pharma Pvt Ltd
  • Lupin Pharmaceuticals, Inc.
  • Mayne Pharma Group Limited
  • Adare Pharmaceuticals, Inc.
  • AdhexPharma
  • Aquestive Therapeutics
目錄
Product Code: KSI061612656

The oral drug delivery market is expected to grow at a CAGR of 6.04% during the forecast period to reach US$148.201 billion by 2027, from US$98.302 billion in 2020. Because oral drug delivery is noninvasive, has a high rate of patient compliance, is easy to handle, and does not require any special sterile conditions, it is considered the most popular method of administration. Hence, it is highly preferred by a wide spectrum of consumers. Because of the prevalence of chronic diseases around the world, these are in high demand. Moreover, rising research and development investment, advancing health expenditure, and an ageing population will all contribute to market expansion throughout the projection period. The oral drug delivery market can be segmented by formulation, application, and geography.

Various factors are expected to drive the oral drug delivery market during the forecast period, including an increase in the number of collaborations among market participants, an increase in the incidence of chronic diseases, and an increase in the global geriatric population.

People are embracing a more sedentary lifestyle as the middle class expands and urbanisation accelerates. Obesity rates and occurrences of diseases like diabetes are rising as a result of this. According to the World Health Organization, the prevalence of chronic disease will rise by 57% by 2020. GlobalData epidemiologists predict that by 2021, India will have 75.26 million diagnosed prevalent cases of type 2 diabetes and 26,000 diagnosed incident cases of endometrial cancer, with 91.72 million and 32,000 cases, respectively, by 2028. According to the American Cancer Society, in 2021, there will be 1.9 million new cancer diagnoses and 608,570 cancer deaths in the United States. According to a report published by Frontiers In Public Health, chronic noncommunicable diseases account for about 80% of the mortality among adults aged 60 in China, with ischemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), and type 2 diabetes being the most common. Smoking, alcohol usage, sedentary activity, and poor nutritional intake are all significant contributors to these diseases. Oral drug delivery systems are expected to become more popular as the prevalence of chronic diseases rises around the world.

According to the World Population Prospects: the 2019 Revision, by 2050, one out of every six people on the planet will be over the age of 65 (16%), from one out of every eleven in 2019 (9%). One in every four people in Europe and North America could be 65 or older by 2050. In 2018, people aged 65 and older outnumbered kids under the age of five for the first time in history on a global level. From 143 million in 2019 to 426 million in 2050, the number of people aged 80 and up is expected to treble. Eastern and South-Eastern Asia's population aged 65 and above nearly doubled from 6% in 1990 to 11% in 2019, while Latin America and the Caribbean's population aged 65 and above nearly doubled from 5% in 1990 to 9% in 2019. The growing geriatric population around the world is also expected to propel market growth in the forecast period.

Moreover, rising research and development and partnerships amongst market players will expand the growth of oral delivery globally. For instance, SWK Holdings Corporation announced the acquisition of Enteris BioPharma in August 2019. This acquisition will allow the company to broaden its product line and provide more advanced products to its clients. This will also allow the company to become a pioneer in the field of orally delivered peptide and small molecule therapies. Similarly, in September 2021, Bio-Thera Solutions signed an agreement with Intract, acquiring the licence to employ the oral delivery system with a single monoclonal antibody that will remain unnamed. Moreover, in November 2021, EsoCap completed private funding round, with existing and new investors participating. The funds will be utilised to further develop and industrialise EsoCap's focused application technology, which will allow for the effective local therapy of esophageal illnesses.

During the projected period, North America is anticipated to dominate the oral drug delivery market.

During the forecast period, North America is expected to have a large market share. Technological advances, rising patent approvals, and research on the usage of nanotechnology for drug delivery in the region are expected to drive the market. For example, Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical firm researching oral drug delivery systems, got a US patent in March 2019. Furthermore, due to the rapid adoption of new drug delivery technologies and the presence of research centres developing innovative drug delivery systems in the country, the United States is expected to hold a significant share of the oral drug delivery systems market in North America during the forecast period.

COVID -19 Insights

The COVID-19 pandemic has had a positive impact on the market for oral drug delivery because the demand for healthcare has increased exponentially around the world as a result of the virus outbreak. Since the disease's emergence, finding effective medications to treat COVID-19 has been a top priority. For instance, Merck and Ridgeback collaborated on the development of Molnupiravir, an oral antiviral medication. The drug delivery market has grown as a result of a lack of appropriate treatment, healthcare infrastructure, and medicine unavailability. Furthermore, as a result of the pandemic, the FDA clearance process became relatively easier, resulting in increased market growth.

Market Segmentation:

  • By Formulation

Tablets

Capsules

Drops

Powder

Liquid or Syrup

Decoction

  • By Application

Disease Treatment

Research/Academic purposes

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • Germany
  • France
  • United Kingdom
  • Spain
  • Others

Middle East and Africa

  • Saudi Arabia
  • Israel
  • Others

Asia Pacific

  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • South Korea
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Powers of Buyers
    • 4.3.3. Threat of Substitutes
    • 4.3.4. Threat of New Entrants
    • 4.3.5. Competitive Rivalry in Industry
  • 4.4. Industry Value Chain Analysis

5. ORAL DRUG DELIVERY MARKET, BY FORMULATION 

  • 5.1. Introduction
  • 5.2. Tablets
  • 5.3. Capsules
  • 5.4. Drops
  • 5.5. Powder
  • 5.6. Liquid or Syrup
  • 5.7. Decoction

6. ORAL DRUG DELIVERY MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Disease Treatment
  • 6.3. Research/Academic purposes

7. ORAL DRUG DELIVERY MARKET, BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. Japan
    • 7.6.3. South Korea
    • 7.6.4. India
    • 7.6.5. Thailand 
    • 7.6.6. South Korea
    • 7.6.7. Taiwan 
    • 7.6.8. Indonesia
    • 7.6.9. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisition, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. Pfizer Inc.
  • 9.2. AstraZeneca
  • 9.3. Alpex Pharma S.A.
  • 9.4. SPI Pharma
  • 9.5. Globela Pharma Pvt Ltd
  • 9.6. Lupin Pharmaceuticals, Inc.
  • 9.7. Mayne Pharma Group Limited
  • 9.8. Adare Pharmaceuticals, Inc.
  • 9.9. AdhexPharma
  • 9.10. Aquestive Therapeutics